NewsBenzinga이뮤너티바이오·라파 래버러토리스, 이스라엘 보건부가 ANKTIVA 승인 발표···BCG 비반응성 NMIBC 성인 환자 치료에 BCG와 병용 투여 승인 이뮤너티바이오·라파 래버러토리스, 이스라엘 보건부가 ANKTIVA 승인 발표···BCG 비반응성 NMIBC 성인 환자 치료에 BCG와 병용 투여 승인 Benzinga 2026.11.09 12:23 (GMT+0) Open on Benzinga Other news Barclays Downgrades Fresenius Medical Care to Underweight Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 Freedom Broker Upgrades Dnow to Buy, Maintains Price Target to $18
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors
